OXiGENE Gets U.S. Patent for Myeloid Neoplasms Treatment - Jumping 7% in After-Hours BY Midnight Trader — 4:10 PM ET 05/26/2015
04:10 PM EDT, 05/26/2015 (MT Newswires) -- OXiGENE ( OXGN) , a biopharmaceutical company developing novel therapies for the treatment of cancer, today said the U.S. Patent and Trademark Office has granted it a patent (U.S. Patent No. 9,040,500) related to the use of OXi4503 for the treatment of myeloid neoplasms, including acute myeloid leukemia (AML).
Price: 1.49, Change: +0.10, Percent Change: +7.1
Need a good stock tip? Check out my jonecool Wiki page, right here on iHub with DD and more!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.